SlideShare une entreprise Scribd logo
1  sur  31
AMANDEEP KAUR
NURSING TUTOR
MMCON
Introduction
 Tuberculosis (TB) is one of the most prevalent infections of
human beings and contributes considerably to illness and death
around the world. It is spread by inhaling tiny droplets of saliva
from the coughs or sneezes of an infected person. It is a slowly
spreading, chronic, granulomatous bacterial infection,
characterized by gradual weight loss.
 TB is the world’s second most common cause of death from
infectious disease after HIV/AIDS.
DEFINITION
 Tuberculosis is the infectious disease primarily
affecting lung parenchyma is most often caused by
Mycobacterium Tuberculosis. It may spread to any
part of the body including meninges, kidney, bones
and lymph-nodes.
TYPES
1. PULMONARY TUBERCULOSIS
2. AVIAN TUBERCULOSIS (Micobacterium avium; of
birds)
3. BOVINE TUBERCULOSIS (Mycobacterium bovis; of
cattle)
4. MILIARY TUBERCULOSIS /DISSEMINATED
TUBERCULOSIS (Invade the blood stream and spread
to all body organs.
INCEDENTS
 With the increased incidence of AIDS, TB has become
a great problem in the U.S., and the world.
 India is the highest TB burden country in the world,
home to 20 percent of cases occurring globally.
 Each year 1.8 million develop TB.
 In India 0.37 million people die because of TB every
year.
Risk factors
 Close contact with some one who have active TB.
 Immuno compromised status (elderly, cancer)
 Drug abuse and alcoholism.
 People lacking adequate health care.
 Pre existing medical conditions (diabetes mellitus, chronic
renal failure).
 Immigrants from countries with higher incidence of TB.
 Institutionalization (long term care facilities)
 Living in substandard conditions.
 Occupation (health care workers)
PATHOPHYSIOLOGY
 (Initial infection or primary infection)
 Entry of micro organism through droplet nuclei
 Bacteria is transmitted to alveoli through airways
 Deposition and multiplication of bacteria
 Bacilli are also transported to other parts of the body via
blood stream and phagocytosis by neutrophils and
macrophages
PATHOPHYSIOLOGY
Mycobacteriam
Pulmonary alveoli
Immune system has lodged in (Alveolar Macrophages)
Detects presence of pathogen and engoulph the bacteria
Mycobacterium bacteria inhibits the Macrophages
(phagosome+ Lysosome) to forms phagolysosome and
remains protected inside the macrophages.
PATHOPHYSIOLOGY
Starts replication inside macrophages.
Primary infection occurs.
Cell mediated immunity gets activated, surrounds the cell to
forms granuloma (3weeks)
Leads to necrosis of tissues at infection site(TERMINUS
GONE FOCUS)
Involve nearby lymph nodes (CONE COMPLEX)
Calcification of cone complex(LATENT T.B.)
CLINICAL MENIFESTATION
CONSTITUTIONAL SYMPTOMS
 Anorexia
 Low grade fever
 Night sweats
 Fatique
 Weight loss
CONT…
PULMONARY SYMPTOMS
 Dyspnea
 Non resolving bronchopneumonia
 Chest tightness
 Non productive cough
 Mucopurulent sputum with hemoptpysis
 Chest pain
 EXTRA PULMONARY SYMPTOMS
 Pain
 Inflammation
ASSESSMENT AND DIAGNOSIS
 HISTORY COLLECTION
 PHYSICAL EXAMINATION
 Clubbing of the fingers or toes (in people with advanced
disease)
 Swollen or tender lymph nodes in the neck or other areas
 Fluid around a lung (pleural effusion)
 Unusual breath sounds (crackles)
 IF MILIARY TB;
 Physical exam may show:
 Swollen liver
 Swollen lymph nodes
 Swollen spleen
Tests may include:
 Biopsy of the affected tissue (rare)
 Bronchoscopy
 Chest CT scan
 Chest x-ray
 Interferon-gamma release blood test such as the QFT-
Gold test to test for TB infection
 Sputum examination and cultures
 Thoracentesis
 Tuberculin skin test (also called a PPD test)
QUANTIFERON GOLD TEST
 QFT-Gold test measures interferon-gamma in the testee's
blood after incubating the blood with specific antigens
from M. Tuberculosis proteins.
TUBERCULIN SKIN TEST:-
 0.1 ml of PPD is injected forearm (s/c)
 After 48-72 hrs check for induration at the site
 If induration is equal to and more than 10mm:-Positive
COMPLECATION
 Bones. Spinal pain and joint destruction may result from TB that
infects your bones(TB spine or pot’s spine)
 Brain(meningitis)
 Liver or kidneys
 Heart(cardiac tamponade)
 Pleural effusion
 Tb pneumonia
 Serious reactions to drug therapy(hepato-toxicity; hypersentivity)
MEDICAL MANAGEMENT
PULMONARY TB is treated primarily with
antituberculosis agents for 6 to 12 months.
 Pharmacological management
 First line antitubercular medications
 Streptomycin 15mg/kg/day.
 Isoniazid or INH (Nydrazid) 5 mg/kg (300 mg
max/day)
 Rifampicin 10 mg/kg/day.
 Pyrazinamide 15 – 30 mg/kg/day.
 Ethambutol (Myambutol) 15 -25 mg/kg daily for 8
weeks and continuing for up to 4 to 7 months
Second line medications
 Capreomycin 12 -15 mg/kg
 Ethionamide 15mg/kg
 Para-aminosalycilate sodium 200 - 300 mg/kg
 Cycloserine 15 mg/kg
 Vitamin b(pyridoxine) usually adminstered with
INH
THIRD LINE DRUGS
 Other drugs that may be useful, but are not on the WHO
list of SLDs:
 Rifabutin
 Macrolides:e.g.,clarithromycin (CLR)
 Linezolid(LZD)
 Thioacetazone(T)
 Thioridazine
 Arginine
DOTS
DOTS (directly observed treatment, short-course), is the name
given to the World Health Organization-recommended
tuberculosis control strategy that combines five components:
1. Government commitment (including both political will at all
levels, and establishing a centralized and prioritized system of
TB monitoring, recording and training)
2. Case detection by sputum smear microscopy
3. Standardized treatment regimen directly observed by a
healthcare worker or community health worker for at least the
first two months
4. A regular drug supply
5. A standardized recording and reporting system that allows
assessment of treatment results
 DOT is especially critical for patients with drug resistant
TB, HIV-infected patients, and those on intermittent
treatment regimens (i.e., 2 or 3 times weekly).
Multiple-drug therapy
 Means taking several different antitubercular drugs at the
same time.
 The standard treatment is to take isoniazid, rifampin,
ethambutol, and pyrazinamide for 2 months. Treatment is
then continued for at least 4months with fewer medicines
NURSING MANAGEMENT
 Assessment
 Obtain history of exposure to TB
 Assess for symptoms of active disease
 Auscultate lungs for crackles
 During drug therapy assess for liver function
NURSING DIAGNOSIS
1. Ineffective breathing pattern related to pulmonary
infection and potential for long term scarring with
decreased lung capacity
 Interventions
 Administer and teach self administration of medications
ordered
 Encourage rest and avoidance of exertion
 Moniter breath sounds respiratory rates , sputum
production and dyspnoea
 Provide supplymental oxygen as ordered
 Encourage increased fluid intake
 Instruct about best position to facilitate drainage
2. Risk for spreading infection related to nature of
disease and patients symptoms
 Be aware that TB is transmitted by respiratory droplets
 Use high efficiency particulate masks for high risk
procedures including endoscopy
 Educate patient to control the spread of infection by
covering mouth and nose while coughing and sneezing
 Isolation of patient
 Instruct about risk of drug resistance if drug regimen is
not strictly and continuosly followed
 Carefully moniter vital signs and observe for temperature
changes
3. Imbalanced nutrition less than body requirement
related to poor appetite ,fatigue and productive
cough
 Explain the importance of eating nutritious diet to
promote healing and defense against infection
 Provide small frequent meals
 Moniter weight of the patient
 Administer vitamin supplyments as ordered
4. Non compliance related to lack of motivation and
lack of treatment
 Educate patient about etiology transmission and
effects of TB
 Review adverse effects of drug therapy
 Participate in observation of medicine taking, weekly
pill counts or programmes designed to increase
compliance with the treatment for TB
 Explain that TB is a communicable disease and that
taking medications is most effective way of
preventing transmission
 Instruct about medications schedule and side effects
Prevention
 ISOLATION
 Ventilate the room
 Cover the mouth
 Wear mask
 Finish entire course of medication
 Vaccinations
Summarization
References
Tuberculosis

Contenu connexe

Tendances (20)

Dengue, DENGUE FEVER, DHS
Dengue, DENGUE FEVER, DHSDengue, DENGUE FEVER, DHS
Dengue, DENGUE FEVER, DHS
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Malaria
MalariaMalaria
Malaria
 
Respiratory tract infections
Respiratory tract infectionsRespiratory tract infections
Respiratory tract infections
 
Leprosy
LeprosyLeprosy
Leprosy
 
Pneumonia seminar presentaation
Pneumonia seminar presentaationPneumonia seminar presentaation
Pneumonia seminar presentaation
 
Diarrhoea
DiarrhoeaDiarrhoea
Diarrhoea
 
Bronchial asthma
Bronchial asthmaBronchial asthma
Bronchial asthma
 
AIDS
AIDSAIDS
AIDS
 
Dots
DotsDots
Dots
 
TUBERCULOSIS
TUBERCULOSISTUBERCULOSIS
TUBERCULOSIS
 
Pneumonia
PneumoniaPneumonia
Pneumonia
 
Meningitis
MeningitisMeningitis
Meningitis
 
Pathogenesis of tuberculosis
Pathogenesis of tuberculosis Pathogenesis of tuberculosis
Pathogenesis of tuberculosis
 
Leprosy
LeprosyLeprosy
Leprosy
 
Myocardial infarction
Myocardial infarctionMyocardial infarction
Myocardial infarction
 
Poliomyelitis
PoliomyelitisPoliomyelitis
Poliomyelitis
 
Peptic ulcer
Peptic ulcerPeptic ulcer
Peptic ulcer
 
Pathophysiology of tuberculosis
Pathophysiology of tuberculosisPathophysiology of tuberculosis
Pathophysiology of tuberculosis
 
Leukemia
LeukemiaLeukemia
Leukemia
 

Similaire à Tuberculosis

Pulmonary tuberculosis (1).pdf
Pulmonary tuberculosis (1).pdfPulmonary tuberculosis (1).pdf
Pulmonary tuberculosis (1).pdfGargee karadkar
 
Tuberculosis by Faith Chelang'at
Tuberculosis by Faith Chelang'atTuberculosis by Faith Chelang'at
Tuberculosis by Faith Chelang'atHarrisonMbohe
 
6.TUBERCLOSIS in respiratory part of study..pptx
6.TUBERCLOSIS in respiratory part of study..pptx6.TUBERCLOSIS in respiratory part of study..pptx
6.TUBERCLOSIS in respiratory part of study..pptxJuma675663
 
Seminar on Pulmonary Tuberculosis
Seminar on Pulmonary TuberculosisSeminar on Pulmonary Tuberculosis
Seminar on Pulmonary Tuberculosissuryakantsatpute1
 
Tuberculosis 2.pptx
Tuberculosis 2.pptxTuberculosis 2.pptx
Tuberculosis 2.pptxMahimaPaul9
 
Tuberculosis.pptx
Tuberculosis.pptxTuberculosis.pptx
Tuberculosis.pptxImtiyaz60
 
Drug Resistance in TB
Drug Resistance in TBDrug Resistance in TB
Drug Resistance in TBswaghmare
 
Pathophysiology and clinical management of tuberculosis
Pathophysiology and clinical management of tuberculosisPathophysiology and clinical management of tuberculosis
Pathophysiology and clinical management of tuberculosisSoujanya Pharm.D
 

Similaire à Tuberculosis (20)

Pulmonary tuberculosis (1).pdf
Pulmonary tuberculosis (1).pdfPulmonary tuberculosis (1).pdf
Pulmonary tuberculosis (1).pdf
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Tuberculosis by Faith Chelang'at
Tuberculosis by Faith Chelang'atTuberculosis by Faith Chelang'at
Tuberculosis by Faith Chelang'at
 
Tuberculosis ppt
Tuberculosis pptTuberculosis ppt
Tuberculosis ppt
 
6.TUBERCLOSIS in respiratory part of study..pptx
6.TUBERCLOSIS in respiratory part of study..pptx6.TUBERCLOSIS in respiratory part of study..pptx
6.TUBERCLOSIS in respiratory part of study..pptx
 
Seminar on Pulmonary Tuberculosis
Seminar on Pulmonary TuberculosisSeminar on Pulmonary Tuberculosis
Seminar on Pulmonary Tuberculosis
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Chemotherapy of Tuberculosis
Chemotherapy of TuberculosisChemotherapy of Tuberculosis
Chemotherapy of Tuberculosis
 
Tuberculosis 2.pptx
Tuberculosis 2.pptxTuberculosis 2.pptx
Tuberculosis 2.pptx
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Tuberculosis
Tuberculosis Tuberculosis
Tuberculosis
 
Anti TB drugs
Anti TB drugsAnti TB drugs
Anti TB drugs
 
Tuberculosis
Tuberculosis  Tuberculosis
Tuberculosis
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
TUBERCULOSIS
TUBERCULOSISTUBERCULOSIS
TUBERCULOSIS
 
Tuberculosis.pptx
Tuberculosis.pptxTuberculosis.pptx
Tuberculosis.pptx
 
Drug Resistance in TB
Drug Resistance in TBDrug Resistance in TB
Drug Resistance in TB
 
Tuberculosis
TuberculosisTuberculosis
Tuberculosis
 
Pathophysiology and clinical management of tuberculosis
Pathophysiology and clinical management of tuberculosisPathophysiology and clinical management of tuberculosis
Pathophysiology and clinical management of tuberculosis
 

Plus de GAMANDEEP

Parathyroid disorders
Parathyroid disordersParathyroid disorders
Parathyroid disordersGAMANDEEP
 
Pheochromocytoma
PheochromocytomaPheochromocytoma
PheochromocytomaGAMANDEEP
 
Disorders of adrenal gland
Disorders of adrenal glandDisorders of adrenal gland
Disorders of adrenal glandGAMANDEEP
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes MellitusGAMANDEEP
 
Special respiratory therapies
Special respiratory therapiesSpecial respiratory therapies
Special respiratory therapiesGAMANDEEP
 
Respiratory failure
Respiratory failureRespiratory failure
Respiratory failureGAMANDEEP
 
Pulmonary embolism1
Pulmonary embolism1Pulmonary embolism1
Pulmonary embolism1GAMANDEEP
 
Pleural effusion
Pleural effusionPleural effusion
Pleural effusionGAMANDEEP
 
Chest physiotherapy
Chest physiotherapyChest physiotherapy
Chest physiotherapyGAMANDEEP
 
Bronchiectases
BronchiectasesBronchiectases
BronchiectasesGAMANDEEP
 
Infection control and safety measures
Infection control and safety measuresInfection control and safety measures
Infection control and safety measuresGAMANDEEP
 
The evolution of nursing
The evolution of nursingThe evolution of nursing
The evolution of nursingGAMANDEEP
 
International classification of disease
International classification of diseaseInternational classification of disease
International classification of diseaseGAMANDEEP
 
Concept of disease causation
Concept of disease causationConcept of disease causation
Concept of disease causationGAMANDEEP
 
Chest injury
Chest injuryChest injury
Chest injuryGAMANDEEP
 
Intracranial pressure measurement
Intracranial pressure measurementIntracranial pressure measurement
Intracranial pressure measurementGAMANDEEP
 
Immunosuppressants final drug ppt
Immunosuppressants  final drug pptImmunosuppressants  final drug ppt
Immunosuppressants final drug pptGAMANDEEP
 

Plus de GAMANDEEP (20)

Parathyroid disorders
Parathyroid disordersParathyroid disorders
Parathyroid disorders
 
Pheochromocytoma
PheochromocytomaPheochromocytoma
Pheochromocytoma
 
Disorders of adrenal gland
Disorders of adrenal glandDisorders of adrenal gland
Disorders of adrenal gland
 
Diabetes Mellitus
Diabetes MellitusDiabetes Mellitus
Diabetes Mellitus
 
Special respiratory therapies
Special respiratory therapiesSpecial respiratory therapies
Special respiratory therapies
 
Respiratory failure
Respiratory failureRespiratory failure
Respiratory failure
 
Pulmonary embolism1
Pulmonary embolism1Pulmonary embolism1
Pulmonary embolism1
 
Pleural effusion
Pleural effusionPleural effusion
Pleural effusion
 
Lung cancer
Lung cancerLung cancer
Lung cancer
 
Empyema
EmpyemaEmpyema
Empyema
 
Chest physiotherapy
Chest physiotherapyChest physiotherapy
Chest physiotherapy
 
Bronchiectases
BronchiectasesBronchiectases
Bronchiectases
 
Asthma ppt
Asthma pptAsthma ppt
Asthma ppt
 
Infection control and safety measures
Infection control and safety measuresInfection control and safety measures
Infection control and safety measures
 
The evolution of nursing
The evolution of nursingThe evolution of nursing
The evolution of nursing
 
International classification of disease
International classification of diseaseInternational classification of disease
International classification of disease
 
Concept of disease causation
Concept of disease causationConcept of disease causation
Concept of disease causation
 
Chest injury
Chest injuryChest injury
Chest injury
 
Intracranial pressure measurement
Intracranial pressure measurementIntracranial pressure measurement
Intracranial pressure measurement
 
Immunosuppressants final drug ppt
Immunosuppressants  final drug pptImmunosuppressants  final drug ppt
Immunosuppressants final drug ppt
 

Dernier

Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 

Dernier (20)

Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 

Tuberculosis

  • 2. Introduction  Tuberculosis (TB) is one of the most prevalent infections of human beings and contributes considerably to illness and death around the world. It is spread by inhaling tiny droplets of saliva from the coughs or sneezes of an infected person. It is a slowly spreading, chronic, granulomatous bacterial infection, characterized by gradual weight loss.  TB is the world’s second most common cause of death from infectious disease after HIV/AIDS.
  • 3. DEFINITION  Tuberculosis is the infectious disease primarily affecting lung parenchyma is most often caused by Mycobacterium Tuberculosis. It may spread to any part of the body including meninges, kidney, bones and lymph-nodes.
  • 4. TYPES 1. PULMONARY TUBERCULOSIS 2. AVIAN TUBERCULOSIS (Micobacterium avium; of birds) 3. BOVINE TUBERCULOSIS (Mycobacterium bovis; of cattle) 4. MILIARY TUBERCULOSIS /DISSEMINATED TUBERCULOSIS (Invade the blood stream and spread to all body organs.
  • 5. INCEDENTS  With the increased incidence of AIDS, TB has become a great problem in the U.S., and the world.  India is the highest TB burden country in the world, home to 20 percent of cases occurring globally.  Each year 1.8 million develop TB.  In India 0.37 million people die because of TB every year.
  • 6. Risk factors  Close contact with some one who have active TB.  Immuno compromised status (elderly, cancer)  Drug abuse and alcoholism.  People lacking adequate health care.  Pre existing medical conditions (diabetes mellitus, chronic renal failure).  Immigrants from countries with higher incidence of TB.  Institutionalization (long term care facilities)  Living in substandard conditions.  Occupation (health care workers)
  • 7. PATHOPHYSIOLOGY  (Initial infection or primary infection)  Entry of micro organism through droplet nuclei  Bacteria is transmitted to alveoli through airways  Deposition and multiplication of bacteria  Bacilli are also transported to other parts of the body via blood stream and phagocytosis by neutrophils and macrophages
  • 8. PATHOPHYSIOLOGY Mycobacteriam Pulmonary alveoli Immune system has lodged in (Alveolar Macrophages) Detects presence of pathogen and engoulph the bacteria Mycobacterium bacteria inhibits the Macrophages (phagosome+ Lysosome) to forms phagolysosome and remains protected inside the macrophages.
  • 9. PATHOPHYSIOLOGY Starts replication inside macrophages. Primary infection occurs. Cell mediated immunity gets activated, surrounds the cell to forms granuloma (3weeks) Leads to necrosis of tissues at infection site(TERMINUS GONE FOCUS) Involve nearby lymph nodes (CONE COMPLEX) Calcification of cone complex(LATENT T.B.)
  • 10. CLINICAL MENIFESTATION CONSTITUTIONAL SYMPTOMS  Anorexia  Low grade fever  Night sweats  Fatique  Weight loss
  • 11. CONT… PULMONARY SYMPTOMS  Dyspnea  Non resolving bronchopneumonia  Chest tightness  Non productive cough  Mucopurulent sputum with hemoptpysis  Chest pain  EXTRA PULMONARY SYMPTOMS  Pain  Inflammation
  • 12. ASSESSMENT AND DIAGNOSIS  HISTORY COLLECTION  PHYSICAL EXAMINATION  Clubbing of the fingers or toes (in people with advanced disease)  Swollen or tender lymph nodes in the neck or other areas  Fluid around a lung (pleural effusion)  Unusual breath sounds (crackles)
  • 13.  IF MILIARY TB;  Physical exam may show:  Swollen liver  Swollen lymph nodes  Swollen spleen
  • 14. Tests may include:  Biopsy of the affected tissue (rare)  Bronchoscopy  Chest CT scan  Chest x-ray  Interferon-gamma release blood test such as the QFT- Gold test to test for TB infection  Sputum examination and cultures  Thoracentesis  Tuberculin skin test (also called a PPD test)
  • 15. QUANTIFERON GOLD TEST  QFT-Gold test measures interferon-gamma in the testee's blood after incubating the blood with specific antigens from M. Tuberculosis proteins. TUBERCULIN SKIN TEST:-  0.1 ml of PPD is injected forearm (s/c)  After 48-72 hrs check for induration at the site  If induration is equal to and more than 10mm:-Positive
  • 16. COMPLECATION  Bones. Spinal pain and joint destruction may result from TB that infects your bones(TB spine or pot’s spine)  Brain(meningitis)  Liver or kidneys  Heart(cardiac tamponade)  Pleural effusion  Tb pneumonia  Serious reactions to drug therapy(hepato-toxicity; hypersentivity)
  • 17. MEDICAL MANAGEMENT PULMONARY TB is treated primarily with antituberculosis agents for 6 to 12 months.  Pharmacological management  First line antitubercular medications  Streptomycin 15mg/kg/day.  Isoniazid or INH (Nydrazid) 5 mg/kg (300 mg max/day)  Rifampicin 10 mg/kg/day.  Pyrazinamide 15 – 30 mg/kg/day.  Ethambutol (Myambutol) 15 -25 mg/kg daily for 8 weeks and continuing for up to 4 to 7 months
  • 18. Second line medications  Capreomycin 12 -15 mg/kg  Ethionamide 15mg/kg  Para-aminosalycilate sodium 200 - 300 mg/kg  Cycloserine 15 mg/kg  Vitamin b(pyridoxine) usually adminstered with INH
  • 19. THIRD LINE DRUGS  Other drugs that may be useful, but are not on the WHO list of SLDs:  Rifabutin  Macrolides:e.g.,clarithromycin (CLR)  Linezolid(LZD)  Thioacetazone(T)  Thioridazine  Arginine
  • 20. DOTS DOTS (directly observed treatment, short-course), is the name given to the World Health Organization-recommended tuberculosis control strategy that combines five components: 1. Government commitment (including both political will at all levels, and establishing a centralized and prioritized system of TB monitoring, recording and training) 2. Case detection by sputum smear microscopy 3. Standardized treatment regimen directly observed by a healthcare worker or community health worker for at least the first two months 4. A regular drug supply 5. A standardized recording and reporting system that allows assessment of treatment results
  • 21.  DOT is especially critical for patients with drug resistant TB, HIV-infected patients, and those on intermittent treatment regimens (i.e., 2 or 3 times weekly).
  • 22. Multiple-drug therapy  Means taking several different antitubercular drugs at the same time.  The standard treatment is to take isoniazid, rifampin, ethambutol, and pyrazinamide for 2 months. Treatment is then continued for at least 4months with fewer medicines
  • 23. NURSING MANAGEMENT  Assessment  Obtain history of exposure to TB  Assess for symptoms of active disease  Auscultate lungs for crackles  During drug therapy assess for liver function
  • 24. NURSING DIAGNOSIS 1. Ineffective breathing pattern related to pulmonary infection and potential for long term scarring with decreased lung capacity  Interventions  Administer and teach self administration of medications ordered  Encourage rest and avoidance of exertion  Moniter breath sounds respiratory rates , sputum production and dyspnoea  Provide supplymental oxygen as ordered  Encourage increased fluid intake  Instruct about best position to facilitate drainage
  • 25. 2. Risk for spreading infection related to nature of disease and patients symptoms  Be aware that TB is transmitted by respiratory droplets  Use high efficiency particulate masks for high risk procedures including endoscopy  Educate patient to control the spread of infection by covering mouth and nose while coughing and sneezing  Isolation of patient  Instruct about risk of drug resistance if drug regimen is not strictly and continuosly followed  Carefully moniter vital signs and observe for temperature changes
  • 26. 3. Imbalanced nutrition less than body requirement related to poor appetite ,fatigue and productive cough  Explain the importance of eating nutritious diet to promote healing and defense against infection  Provide small frequent meals  Moniter weight of the patient  Administer vitamin supplyments as ordered
  • 27. 4. Non compliance related to lack of motivation and lack of treatment  Educate patient about etiology transmission and effects of TB  Review adverse effects of drug therapy  Participate in observation of medicine taking, weekly pill counts or programmes designed to increase compliance with the treatment for TB  Explain that TB is a communicable disease and that taking medications is most effective way of preventing transmission  Instruct about medications schedule and side effects
  • 28. Prevention  ISOLATION  Ventilate the room  Cover the mouth  Wear mask  Finish entire course of medication  Vaccinations